This note states the assumptions and the arithmetic of one model of BIOFIL CHEM & PHARMA LTD, built on its filed FY26 standalone statements. The value is the outcome of the assumptions below and nothing else; it is not a fair value, a target or a recommendation.
Assumptions
Input
This model
Filed reference
Revenue growth, 5 years
-5% a year
FY26 (15.0)% · 5-yr CAGR (4.5)%
EBITDA margin
2.3%
FY26 2.3% · 5-yr average 3.3%
Depreciation · capex, % of revenue
1% · 0.7%, fading to 1.2× depreciation
FY26 1.0% · 0.7%
Working capital, % of added revenue · tax
51.2% · 19.2%
187 working-capital days · effective 19.2%
Discount rate
11.00%
1-yr beta 0.87
After FY31
5% flat · mid-year discounting
—
Net debt · non-controlling interest · non-operating investments
₹3 · ₹0 · ₹0 cr
FY26 net debt ₹3 cr
Shares
1.63 crore
1.63 crore today
Source: SEBI results XBRL as filed with BSE/NSE, exchange prices; the reader's assumptions.
Projected cash flow to the firm
₹ crore
FY26
FY27
FY28
FY29
FY30
FY31
Revenue
28
27
26
24
23
22
growth %
(15.0)
(5.0)
(5.0)
(5.0)
(5.0)
(5.0)
EBITDA
1
1
1
1
1
1
Depreciation
(0)
(0)
(0)
(0)
(0)
(0)
NOPAT
0
0
0
0
0
0
less capex
(0)
(0)
(0)
(0)
(0)
(0)
less working-capital build
—
1
1
1
1
1
Free cash flow to firm
—
1
1
1
1
1
Present value
1
1
1
1
0
Source: the model; base year as filed.
Every figure is the reader's model over filed numbers · No rating, target or fair value is expressedmarketping.in
Model Note · BIOFIL CHEM & PHARMA LTD · 29 October 2026Page 2 of 2
From enterprise to equity
PV of the 5 explicit years
4
PV of the terminal value (69% of EV)
8
Enterprise value
12
less net debt
(3)
less non-controlling interest
0
add non-operating investments
0
Equity value
9
÷ 1.63 crore shares
₹5
Source: the model.
Sensitivity, ₹ per share
WACC ↓ · terminal growth →
4.0%
4.5%
5.0%
5.5%
6.0%
10.0%
6
6
7
7
8
10.5%
5
6
6
7
7
11.0%
5
5
5
6
6
11.5%
4
5
5
5
6
12.0%
4
4
4
5
5
Source: the model; n/a where terminal growth reaches the discount rate.
Statement
This note is the reader's own model over publicly filed information: SEBI results XBRL filed with BSE and NSE and exchange price data, assembled by MarketPing software; every assumption above is the reader's. It contains no research recommendation, no price target and no opinion by MarketPing on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Historical per-share figures are on the current share count. Where a figure is unavailable the table shows a dash rather than an estimate. Nothing here constitutes investment advice, an offer or a solicitation.
Every figure is the reader's model over filed numbers · No rating, target or fair value is expressedmarketping.in
